Immune Human Antibody Libraries for Infectious Diseases

2017 ◽  
pp. 61-78
Author(s):  
Soo Khim Chan ◽  
Theam Soon Lim
Keyword(s):  
Infectious Diseases ◽  
Human Antibody ◽  
Antibody Libraries

Human antibody libraries

1996 ◽  
Vol 2 (1) ◽  
pp. 72-73
Author(s):  
T.J. Vaughan ◽  
A.J. Williams ◽  
K. Pritchard ◽  
J.K. Osbourn ◽  
A.R. Pope ◽  
...  
Keyword(s):  
Human Antibody ◽  
Antibody Libraries

scholarly journals An improved yeast transformation method for the generation of very large human antibody libraries

2010 ◽  
Vol 23 (4) ◽  
pp. 155-159 ◽  
Author(s):  
Lorenzo Benatuil ◽  
Jennifer M. Perez ◽  
Jonathan Belk ◽  
Chung-Ming Hsieh
Keyword(s):  
Transformation Method ◽  
Human Antibody ◽  
Yeast Transformation ◽  
Antibody Libraries

scholarly journals Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus

2017 ◽  
Vol 91 (14) ◽  
Author(s):  
Christina L. Gardner ◽  
Chengqun Sun ◽  
Thomas Luke ◽  
Kanakatte Raviprakash ◽  
Hua Wu ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Protective Efficacy ◽  
Venezuelan Equine Encephalitis Virus ◽  
Encephalitis Virus ◽  
High Dose ◽  
High Morbidity ◽  
Human Antibody ◽  
Venezuelan Equine Encephalitis ◽  
Equine Encephalitis Virus ◽  
Antibody Preparations

ABSTRACT Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne RNA virus that causes low mortality but high morbidity rates in humans. In addition to natural outbreaks, there is the potential for exposure to VEEV via aerosolized virus particles. There are currently no FDA-licensed vaccines or antiviral therapies for VEEV. Passive immunotherapy is an approved method used to protect individuals against several pathogens and toxins. Human polyclonal antibodies (PAbs) are ideal, but this is dependent upon serum from convalescent human donors, which is in limited supply. Non-human-derived PAbs can have serious immunoreactivity complications, and when “humanized,” these antibodies may exhibit reduced neutralization efficiency. To address these issues, transchromosomic (Tc) bovines have been created, which can produce potent neutralizing human antibodies in response to hyperimmunization. In these studies, we have immunized these bovines with different VEEV immunogens and evaluated the protective efficacy of purified preparations of the resultant human polyclonal antisera against low- and high-dose VEEV challenges. These studies demonstrate that prophylactic or therapeutic administration of the polyclonal antibody preparations (TcPAbs) can protect mice against lethal subcutaneous or aerosol challenge with VEEV. Furthermore, significant protection against unrelated coinfecting viral pathogens can be conferred by combining individual virus-specific TcPAb preparations. IMPORTANCE With the globalization and spread or potential aerosol release of emerging infectious diseases, it will be critical to develop platforms that are able to produce therapeutics in a short time frame. By using a transchromosomic (Tc) bovine platform, it is theoretically possible to produce antigen-specific highly neutralizing therapeutic polyclonal human antibody (TcPAb) preparations in 6 months or less. In this study, we demonstrate that Tc bovine-derived Venezuelan equine encephalitis virus (VEEV)-specific TcPAbs are highly effective against VEEV infection that mimics not only the natural route of infection but also infection via aerosol exposure. Additionally, we show that combinatorial TcPAb preparations can be used to treat coinfections with divergent pathogens, demonstrating that the Tc bovine platform could be beneficial in areas where multiple infectious diseases occur contemporaneously or in the case of multipathogen release.

Principles and application of antibody libraries for infectious diseases

2014 ◽  
Vol 36 (12) ◽  
pp. 2381-2392 ◽  
Author(s):  
Bee Nar Lim ◽  
Gee Jun Tye ◽  
Yee Siew Choong ◽  
Eugene Boon Beng Ong ◽  
Asma Ismail ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Antibody Libraries

scholarly journals Use of bacteriophage for discovery of therapeutically relevant antibodies against infectious diseases

2019 ◽  
Vol 40 (1) ◽  
pp. 33
Author(s):  
Martina L Jones
Keyword(s):  
Monoclonal Antibodies ◽  
Molecular Biology ◽  
Infectious Diseases ◽  
Phage Display ◽  
Clinical Use ◽  
Diagnostic Use ◽  
Inflammatory Conditions ◽  
Wide Range ◽  
Antibody Libraries ◽  
Bacteria Culture

Scientists George P Smith and Gregory Winter were recently awarded half of the 2018 Nobel Prize for Chemistry for developing a technology to display exogenous peptides and proteins on the surface of bacteriophage. ‘Phage display' has revolutionised the development of monoclonal antibodies, allowing fully human-derived antibodies to be isolated from large antibody libraries. It has been used for the discovery of many blockbuster drugs, including Humira (adalimumab), the highest selling drug yearly since 2012, with US$18.4b in sales globally in 20171. Phage display can be used to isolate antibodies to almost any antigen for a wide range of applications including clinical use (for cancer, inflammatory conditions and infectious diseases), diagnostic use or as research tools. The technology is accessible to any laboratory equipped for molecular biology and bacteria culture.

Generation of Naive Human Antibody Libraries

2001 ◽  
pp. 93-108 ◽  
Author(s):  
Catherine Hutchings ◽  
Sara Carmen ◽  
Simon Lennard
Keyword(s):  
Human Antibody ◽  
Antibody Libraries

scholarly journals Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential

mAbs ◽  
2013 ◽  
Vol 6 (1) ◽  
pp. 130-142 ◽  
Author(s):  
Philipp Diebolder ◽  
Armin Keller ◽  
Stephanie Haase ◽  
Anne Schlegelmilch ◽  
Jonathan D Kiefer ◽  
...  
Keyword(s):  
Lymph Node ◽  
Therapeutic Potential ◽  
Antibody Fragments ◽  
Human Antibody ◽  
Antibody Libraries
Sign in / Sign up

Export Citation Format

Share Document